Galmed Pharmaceuticals Ltd.
GLMD
$1.07
$0.1111.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.18% | 3.83% | -16.10% | -15.91% | -5.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.82% | 12.59% | -10.88% | -16.20% | -12.90% |
| Operating Income | -4.82% | -12.59% | 10.88% | 16.20% | 12.90% |
| Income Before Tax | -37.57% | -48.26% | -15.56% | -8.75% | 16.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.57% | -48.26% | -15.56% | -8.75% | 16.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.57% | -48.26% | -15.56% | -8.75% | 16.07% |
| EBIT | -4.82% | -12.59% | 10.88% | 16.20% | 12.90% |
| EBITDA | -5.29% | -13.70% | 11.85% | 16.97% | 13.67% |
| EPS Basic | 84.34% | 78.75% | 81.67% | 82.78% | 52.84% |
| Normalized Basic EPS | 86.70% | 80.25% | 82.54% | 83.87% | 55.11% |
| EPS Diluted | 84.34% | 78.75% | 81.67% | 82.78% | 52.84% |
| Normalized Diluted EPS | 86.70% | 80.25% | 82.54% | 83.87% | 55.11% |
| Average Basic Shares Outstanding | 472.50% | 387.86% | 330.97% | 457.14% | 224.38% |
| Average Diluted Shares Outstanding | 472.50% | 387.86% | 330.97% | 457.14% | 224.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |